<DOC>
	<DOCNO>NCT00939510</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth prostate cancer block blood flow tumor . GM-CSF may stimulate immune system different way stop tumor cell grow . Giving lenalidomide together GM-CSF may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose lenalidomide give together GM-CSF see well work treat patient prostate cancer .</brief_summary>
	<brief_title>Lenalidomide GM-CSF Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Establish safety predetermine target dose , target dose tolerable , find maximum tolerate dose lenalidomide administer combination sargramostim patient androgen-independent prostate cancer . - Evaluate preliminary efficacy regimen ascertain whether additional study lenalidomide warrant patient androgen-independent prostate cancer . - Evaluate safety regimen patient . - Describe effect regimen serum cytokine ( e.g. , TNF-α , bFGF , sIL2R , IL-8 , IL-12 ) serum VEGF level . - Assess co-stimulatory effect regimen CD4+ , CD8+ , CD83 , CD86 cell . OUTLINE : This phase I , dose-escalation study lenalidomide follow phase II study . Patients receive oral lenalidomide day 1-21 sargramostim subcutaneously day 1 , 3 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood sample collect periodically correlative biomarker immunological laboratory study . After completion study therapy , patient follow 30 day every 3 month thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Androgenindependent disease Testosterone ≤ 50 ng/mL Is currently receive luteinizing hormonereleasing hormone agonist maintenance undergone prior orchiectomy testosterone suppression Progressive disease , define ≥ 1 following : Clinical radiographic evidence metastasis progress irrespective PSA change Asymptomatic ( nonopioid require ) boneonly metastatic disease rise PSA separate measurement ≥ 1 week apart No symptomatic bone metastases Biochemical progression ( PSAonly disease ) , define absolute PSA value ≥ 2.0 ng/mL 3 separate measurement ≥ 2 week apart PSA double time ≤ 10 month No evidence CNS ( brain leptomeningeal ) metastases pleural and/or pericardial effusion PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Serum creatinine ≤ 2.0 mg/dL AST &lt; 3 time normal Bilirubin &lt; 1.5 mg/dL PT PTT normal Calcium normal Fertile patient must use effective contraception ≥ 28 day completion study therapy Agrees abstain donate blood , semen , sperm ≥ 28 day completion study therapy No preexist peripheral neuropathy &gt; grade 1 No active unresolved infection No know contraindication lenalidomide sargramostim No malignancy within past 5 year , except curatively treat basal cell squamous cell carcinoma skin stage Ta transitional cell carcinoma bladder PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy metastatic prostate cancer More 1 year since prior adjuvant and/or neoadjuvant therapy More 4 week since prior flutamide ( 6 week antiandrogens ) No prior thalidomide lenalidomide At least 4 week since prior surgery externalbeam radiotherapy recover At least 6 week since prior radiopharmaceutical therapy , include samarium153 strontium89 , recover No initiation bisphosphonate therapy within 1 month study therapy Patients stable dos bisphosphonates show subsequent tumor progression may continue receive bisphosphonates Concurrent daily aspirin prevention thrombotic event require Patients intolerant aspirin may receive lowdose warfarin prophylaxis No concurrent investigational agent No concurrent anticancer therapy , include radiotherapy thalidomide</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>hormone-resistant prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>